- Roche is seeking cash compensation of “any available damages” and a court order blocking U.S. sales of Ultomiris, according to a
complaintfiled Tuesday in federal court in Wilmington, Delaware
- Ultomiris is taken every eight weeks, a more convenient dosing than Alexion’s blockbuster Soliris, which is taken every two weeks
- The drugs are used to treat potentially fatal blood diseases including paroxysmal nocturnal hemoglobinuria (PNH)
- Alexion sells both Soliris and Ultomiris, but makes most of its revenue from Soliris sales, making it ...
Nov. 12, 2019, 10:07 PM